ACTRN12609000812291已完成未知
Prospective, open labelled, randomised daily wear trial comparing the ocular response and product performance between 1 Day Acuvue Moist, 1 Day Acuvue TruEye and Acuvue Oasys contact lenses in new and experienced wearers
Alcon Laboratories0 个研究点目标入组 120 人开始时间: 2009年9月17日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants in this trial must:
- •- be able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
- •- be at least 18 years old;
- •- be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator;
- •- have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses;
- •- Has vision correctable to at least 6/12 (20/40) or better in each eye with contact lenses;
- •- may be experienced or inexperienced at wearing contact lenses.
排除标准
- •Participants in this trial must not have:
- •- Any pre-existing ocular irritation, injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses;
- •- Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosis. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants;
- •- Use of or a need for concurrent category S3 and above ocular medication up to 12 weeks prior to and during the trial;
- •- Use of or a need for any systemic medication or topical medications which may alter normal ocular findings/are known to affect a participant’s ocular health/physiology or contact lens performance either in an adverse or beneficial manner;
- •N.B. Systemic antihistamines are allowed on an ‘as needed basis’, provided they are not used prophylactically during the trial;
- •- Eye surgery within 12 weeks immediately prior to enrolment for this trial;
- •- Previous corneal refractive surgery;
- •- Contraindications to contact lens wear;
- •- Currently enrolled in another clinical trial;
- •- Participation in a clinical trial within the previous 2 weeks or participation in a ‘short term’ clinical trial within the previous 48 hours;
- •- Be pregnant
- •- Allergy or intolerance to topical anaesthetics
研究者
相似试验
已完成
3 期
A prospective, open-label, daily wear, parallel group, randomised clinical trial assessing an investigational contact lens care solution for comfort, safety and efficacy with four commercially available contact lenses, worn bilaterally over three months, in both experienced and new contact lens wearersACTRN12609000640202Abbott Medical Optics, Inc160
已完成
不适用
A randomised comparison of two different methods of intrabronchial lignocaine delivery during flexible bronchoscopySurgeryAnaesthesiaocal anaesthetic delivery in bronchoscopyISRCTN77331907ancashire Teaching Hospitals NHS Trust (UK)100
招募中
1 期
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptomsPsoriatic arthritisMedDRA version: 21.1Level: PTClassification code: 10037162Term: Psoriatic arthropathy Class: 100000004859CTIS2023-508251-39-00niversitaetsklinikum Erlangen AöR370
进行中（未招募）
1 期
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptomsPsoriatic arthritisEUCTR2020-001899-14-DEniversitätsklinikum Erlangen270
Unknown
4 期
evaluate the safety and effectiveness of Fixed Dose Combinations of Bupivacaine and Fentanyl epidural injection in post-operative and labour paiCTRI/2020/07/026903Troikaa Pharmaceuticals Ltd